Publication | Open Access

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Surgical OncologyMalignant Pleural MesotheliomaMedicinePathologyPleural DiseaseSakk 17/16Third-line Palliative TherapyOncologyRadiation Oncology